GSK’s Blenrep Nears FDA Review for Myeloma

GlaxoSmithKline (GB:GSK) has released an update.

GlaxoSmithKline’s Blenrep combinations for treating relapsed multiple myeloma have been accepted for review by the US FDA, supported by promising results from the DREAMM-7 and DREAMM-8 trials. These trials showed significant improvements in progression-free survival and overall survival, potentially redefining treatment options for this challenging cancer. A decision from the FDA is anticipated by July 2025.

For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.